Patient #8 had a missense MLL3 mutation in the HER2‐positive DCIS and HER2‐negative invasive component, whereas the HER2‐negative DCIS component presented with a different nonsense MLL3 mutation. Here, ERBB2 is linked to ductal breast carcinoma in situ.